Pulmonary edema refers to fluid accumulation in the air sacs (alveoli) of the lungs. It causes breathing difficulties and can be potentially life-threatening if not treated on time. Pulmonary edema is generally caused by heart failure, cardiogenic shock, lung disease, near drowning or high altitude sickness. Growing geriatric population is more prone to comorbidities like cardiovascular and respiratory diseases that increase the risk of pulmonary edema. According to the United Nations, the number of people aged 65 years or above is projected to grow from 703 million in 2019 to 1.5 billion in 2050.

The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The growing elderly population base across the world is a key driver augmenting the pulmonary edema therapeutics market growth over the forecast period. As per the data by the United Nations, the number of people aged 65 years and above is projected to grow from 703 million in 2019 to 1.5 billion in 2050. The geriatric population is more prone to chronic respiratory and cardiovascular disorders that elevate the risks of pulmonary edema. This rising prevalence of underlying conditions such as chronic obstructive pulmonary disease (COPD), asthma, and congestive heart failure among the aging population will significantly boost the demand for pulmonary edema therapeutics in the coming years.

SWOT Analysis

Strength: The pulmonary edema therapeutics market has several treatment options. Drugs like diuretics, vasodilators, and more are used to treat pulmonary edema.
Weakness: Lack of awareness about pulmonary edema and its treatment options in some regions. side effects of drugs used for treatment.
Opportunity: Increasing focus on development of novel therapies. Growing geriatric population worldwide prone to pulmonary edema.
Threats: Patent expiries of blockbuster drugs. Stringent regulations for approval of new therapies.

Key Takeaways

The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.

North America dominates the global pulmonary edema therapeutics market currently owing to high awareness levels about the condition and availability of advanced healthcare facilities. Asia Pacific is expected to register the highest CAGR over the forecast period supported by growing healthcare expenditure and expanding patient pool in India and China.

Key players related content comprises

Key players operating in the pulmonary edema therapeutics market are Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, Jovi S.L. Crayola LLC and Faber-Castell AG collectively hold major market share currently.

For more details on the report, Read- https://www.ukwebwire.com/pulmonary-edema-therapeutics-market-demand-share-analysis/